Journal: Blood Advances
Article Title: In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis
doi: 10.1182/bloodadvances.2018026179
Figure Lengend Snippet: Treatment with AGS-16C3F decreased the number of ROSAKIT D816V-Gluccells in hematopoietic organs. Mice were euthanized 4 days after the last injection of AGS-16C3F. (A,C) Fluorescence-activated cell sorter analyses of the percentage of hCD45+/KIT+ in BM (A) and spleen (C). (B,D) Absolute numbers of neoplastic MCs in BM (B) and spleen (D), calculated by: total cell number in 1 femur and in total spleen × % of hCD45+/KIT+ cells in BM and spleen. (E) The femurs from 4 mice were collected and stained immunohistochemically with anti-human CD45 Ab. The sections were counterstained with hematoxylin. *P < .05; **P < .01.
Article Snippet: ROSA KIT D816V-Gluc cell burden was determined by flow cytometry analysis and cell numeration in mouse peripheral blood (PB), BM, and spleen samples, using phycoerythrin-conjugated monoclonal antibodies (mAbs) directed against human KIT (CD117; Beckman Coulter, Villepinte, France), phycoerythrin/Cy7 conjugated anti-human CD45 mAbs, and an APC-Cy7-conjugated rat anti-mouse CD45 mAb, both from BD Biosciences.
Techniques: Injection, Fluorescence, Staining